| GTO ID | GTC3756 |
| Trial ID |
NCT06253663
|
| Disease |
Mantle Cell Lymphoma
|
B-Precursor Acute Lymphoblastic Leukemia
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-X19|Tecartus|Brexucabtagene autoleucel |
| Location approved | US, EU, UK, Australia, Canada |
| Phase | Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia |
| Year | 2024 |
| Country | Japan |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KT-US-472-0149 |